The ZBI is a 22 item scale. Each item on the interview is a statement which the caregiver is asked to endorse using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly Always). Total scores range from 0 (low burden) to 88 (high burden)
The STAI State (STAI-S) is a 20-item 4-point Likert scale commonly used measure of state anxiety. Respondents report the intensity of their anxiety at that moment on a 4-point scale where 1 = not at all and 4 = very much so. Total scores range from 20 to 80 and higher scores indicate greater anxiety.
Baseline
Group
Value
95% CI
Tele-Savvy Group
35.07
± 11.96
Attention Control Group
34.61
± 13.13
Usual Care Group
33.41
± 11.61
Month 3
Group
Value
95% CI
Tele-Savvy Group
32.90
± 12.31
Attention Control Group
32.96
± 11.50
Usual Care Group
35.00
± 12.15
Month 6
Group
Value
95% CI
Tele-Savvy Group
31.22
± 9.97
Attention Control Group
34.07
± 11.83
Usual Care Group
35.41
± 12.93
Center for Epidemiological Studies Depression Scale - Revised (CESD-R) ScorePrimary· Baseline, Month 3, Month 6
The CESD-R is a 20 item Likert scale scored 0-3 with somatic and psychological subscales. Total scores range from 0 to 60, with high scores indicating greater depressive symptoms.
Baseline
Group
Value
95% CI
Tele-Savvy Group
13.14
± 9.98
Attention Control Group
12.06
± 10.09
Usual Care Group
11.08
± 8.25
Month 3
Group
Value
95% CI
Tele-Savvy Group
10.45
± 9.23
Attention Control Group
10.52
± 9.18
Usual Care Group
12.07
± 8.60
Month 6
Group
Value
95% CI
Tele-Savvy Group
10.51
± 8.16
Attention Control Group
11.65
± 10.08
Usual Care Group
12.93
± 9.28
Revised Memory and Behavior Problem Checklist (RMBPC) Reaction ScoreSecondary· Baseline, Month 3, Month 6
The RMBPC is a 24-item instrument that assesses behaviors in persons with dementia and caregiver responses to them. Caregiver reactions to behaviors are scored as 0 = not at all upsetting to 4 = extremely upsetting. Total caregiver reaction scores range from 0 to 96 with higher scores indicating greater feelings of being upset by behaviors of those with dementia that they are providing care for.
The Caregiving Competence Subscale of the Pearlin Mastery, Loss, and Competence instrument has 4 items that are responded to on a 4-point Likert scale where 1 = not at all and 4 = very much. Total scores for this subscale range from 4 to 16 and higher scores indicate greater feelings of competence with caregiving.
Baseline
Group
Value
95% CI
Tele-Savvy Group
12.11
± 2.12
Attention Control Group
12.44
± 1.94
Usual Care Group
12.31
± 2.14
Month 3
Group
Value
95% CI
Tele-Savvy Group
13.21
± 1.46
Attention Control Group
12.49
± 1.98
Usual Care Group
11.98
± 2.27
Month 6
Group
Value
95% CI
Tele-Savvy Group
13.07
± 1.71
Attention Control Group
12.62
± 2.15
Usual Care Group
12.52
± 2.19
Pearlin Mastery, Loss, and Competence - Management of Situation Subscale ScoreSecondary· Baseline, Month 3, Month 6
The Management of Situation Subscale of the Pearlin Mastery, Loss, and Competence instrument has 4 items that are responded to on a 4-point Likert scale where 1 = never and 4 = very often. Total scores for this subscale range from 4 to 16 and higher scores indicate greater management of caregiving situations.
The PSS is 14-item Likert-type questionnaire. Responses are given on a 5-point scale where 0 = never and 4 = very often. Total scores range from 0 to 56 and certain items are reverse scored so that higher total scores reflect higher perceived stress.
Baseline
Group
Value
95% CI
Tele-Savvy Group
23.50
± 8.93
Attention Control Group
22.66
± 8.21
Usual Care Group
21.73
± 7.71
Month 3
Group
Value
95% CI
Tele-Savvy Group
20.77
± 6.93
Attention Control Group
21.24
± 7.63
Usual Care Group
23.86
± 6.74
Month 6
Group
Value
95% CI
Tele-Savvy Group
20.72
± 7.10
Attention Control Group
22.14
± 8.08
Usual Care Group
23.50
± 7.36
Sponsor's own description
The purpose of this study is to test the psychoeducational program "Tele-Savvy." Tele-Savvy is an internet based, group education program developed from an in person program called Savvy Caregiver. Participants will be randomly assigned to either the Tele-Savvy group (receiving only the Tele-Savvy education) or the Healthy Living Education Program (receiving healthy lifestyle education and then Tele-Savvy education 6 months later) or a usual care group (receiving Tele-Savvy education 6 months later). Each program takes 43 days to complete.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT05080777 — Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
· NA
· completed
Other recruiting trials for Alzheimer Disease
Currently open trials in the same condition.
NCT07290387 — Tele-Savvy for Latino Caregivers
· NA
· recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
· NA
· recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease
· NA
· recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
· Phase 3
· recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
· NA
· recruiting
Other Emory University trials
Trials by the same sponsor.
NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study
· NA
· withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait
· NA
· not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose
· NA
· not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I
· Phase 2
· recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 13 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03033875.